Evidence for the elevation of serum carcinoembryonic antigen and tumor associated glycoprotein-72 levels in patients administered interferons
Sera were collected from 111 patients diagnosed with adenocarcinoma or nonadenocarcinoma malignancies who received different schedules of interferon (IFN)-gamma or IFN-beta ser alone or in combination. Serum carcinoembryonic antigen (CEA) and tumor-associated glycoprotein-72 (TAG-72) antigen levels...
Gespeichert in:
Veröffentlicht in: | Cancer research (Chicago, Ill.) Ill.), 1991-08, Vol.51 (16), p.4155-4163 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4163 |
---|---|
container_issue | 16 |
container_start_page | 4155 |
container_title | Cancer research (Chicago, Ill.) |
container_volume | 51 |
creator | GREINER, J. W GUADAGNI, F GOLDSTEIN, D BORDEN, E. C RITTS, R. E WITT, P LOBUGLIO, A. F SALEH, M. N SCHLOM, J |
description | Sera were collected from 111 patients diagnosed with adenocarcinoma or nonadenocarcinoma malignancies who received different schedules of interferon (IFN)-gamma or IFN-beta ser alone or in combination. Serum carcinoembryonic antigen (CEA) and tumor-associated glycoprotein-72 (TAG-72) antigen levels were measured to determine whether interferon could enhance the tumor shedding and, thereby, the serum level of either tumor antigen. Less than 10% of the sera samples from patients diagnosed with nonadenocarcinoma malignancies (e.g., hairy cell leukemia, melanoma) had positive titers of TAG-72 or CEA, and interferon neither increased nor resulted in the appearance of either tumor antigen in those sera. In contrast, 59.2% and 75.4% of the patients with adenocarcinoma had positive serum levels of TAG-72 and CEA, respectively, prior to interferon. IFN-gamma and IFN-beta ser alone or in combination significantly increased serum TAG-72 or CEA in approximately 65% of those patients. The results suggest that interferon administration to patients with adenocarcinoma can result in increased serum levels of selected tumor-associated antigens used in the diagnosis of malignancy. These preliminary findings may be important in the development of new strategies to obtain more sensitive tumor antigen serum assays for the diagnosis and monitoring for disease progression of adenocarcinoma. |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_80732868</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80732868</sourcerecordid><originalsourceid>FETCH-LOGICAL-h300t-ab511edc5582f08f6f7ea135570200da037d5bdc8ea74daf01d7e3c07bd2c3af3</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhhdRaq3-BCEH8baQbDZNepTiFxS86LnMJpM2spvUJFvoj_A_G3Dx6ulheJ95GeasmjPBVS3bVpxXc0qpqkUrm8vqKqXPMgpGxayasRWVSrF59f14dAa9RmJDJHmPBHs8QnbBk2BJwjgOREPUzgccungK3mkCPrsd-kJD8jiUTUgpaAcZDdn1Jx0OMWR0vpYNKX3YJ-I8OZRe9DkRMIPzLmWMxXe-0GIMPl1XFxb6hDcTF9XH0-P7-qXevD2_rh829Z5TmmvoBGNotBCqsVTZpZUIjAshaUOpAcqlEZ3RCkG2BixlRiLXVHam0RwsX1T3v73lzK8RU94OLmnse_AYxrRVVPJGLdW_IlsywZaCFvF2EsduQLM9RDdAPG2nR5f8bsohaehtBK9d-tPaVSs44_wHF46Lew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16151650</pqid></control><display><type>article</type><title>Evidence for the elevation of serum carcinoembryonic antigen and tumor associated glycoprotein-72 levels in patients administered interferons</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>GREINER, J. W ; GUADAGNI, F ; GOLDSTEIN, D ; BORDEN, E. C ; RITTS, R. E ; WITT, P ; LOBUGLIO, A. F ; SALEH, M. N ; SCHLOM, J</creator><creatorcontrib>GREINER, J. W ; GUADAGNI, F ; GOLDSTEIN, D ; BORDEN, E. C ; RITTS, R. E ; WITT, P ; LOBUGLIO, A. F ; SALEH, M. N ; SCHLOM, J</creatorcontrib><description>Sera were collected from 111 patients diagnosed with adenocarcinoma or nonadenocarcinoma malignancies who received different schedules of interferon (IFN)-gamma or IFN-beta ser alone or in combination. Serum carcinoembryonic antigen (CEA) and tumor-associated glycoprotein-72 (TAG-72) antigen levels were measured to determine whether interferon could enhance the tumor shedding and, thereby, the serum level of either tumor antigen. Less than 10% of the sera samples from patients diagnosed with nonadenocarcinoma malignancies (e.g., hairy cell leukemia, melanoma) had positive titers of TAG-72 or CEA, and interferon neither increased nor resulted in the appearance of either tumor antigen in those sera. In contrast, 59.2% and 75.4% of the patients with adenocarcinoma had positive serum levels of TAG-72 and CEA, respectively, prior to interferon. IFN-gamma and IFN-beta ser alone or in combination significantly increased serum TAG-72 or CEA in approximately 65% of those patients. The results suggest that interferon administration to patients with adenocarcinoma can result in increased serum levels of selected tumor-associated antigens used in the diagnosis of malignancy. These preliminary findings may be important in the development of new strategies to obtain more sensitive tumor antigen serum assays for the diagnosis and monitoring for disease progression of adenocarcinoma.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 1907881</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adenocarcinoma - blood ; Adenocarcinoma - immunology ; Adenocarcinoma - therapy ; Antigens, Neoplasm - analysis ; Antineoplastic agents ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Carcinoembryonic Antigen - analysis ; Female ; Glycoproteins - analysis ; Humans ; Immunotherapy ; Interferon Type I - therapeutic use ; Interferon-gamma - therapeutic use ; Medical sciences ; Neoplasms - blood ; Neoplasms - immunology ; Neoplasms - therapy ; Pharmacology. Drug treatments</subject><ispartof>Cancer research (Chicago, Ill.), 1991-08, Vol.51 (16), p.4155-4163</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4945313$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1907881$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GREINER, J. W</creatorcontrib><creatorcontrib>GUADAGNI, F</creatorcontrib><creatorcontrib>GOLDSTEIN, D</creatorcontrib><creatorcontrib>BORDEN, E. C</creatorcontrib><creatorcontrib>RITTS, R. E</creatorcontrib><creatorcontrib>WITT, P</creatorcontrib><creatorcontrib>LOBUGLIO, A. F</creatorcontrib><creatorcontrib>SALEH, M. N</creatorcontrib><creatorcontrib>SCHLOM, J</creatorcontrib><title>Evidence for the elevation of serum carcinoembryonic antigen and tumor associated glycoprotein-72 levels in patients administered interferons</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Sera were collected from 111 patients diagnosed with adenocarcinoma or nonadenocarcinoma malignancies who received different schedules of interferon (IFN)-gamma or IFN-beta ser alone or in combination. Serum carcinoembryonic antigen (CEA) and tumor-associated glycoprotein-72 (TAG-72) antigen levels were measured to determine whether interferon could enhance the tumor shedding and, thereby, the serum level of either tumor antigen. Less than 10% of the sera samples from patients diagnosed with nonadenocarcinoma malignancies (e.g., hairy cell leukemia, melanoma) had positive titers of TAG-72 or CEA, and interferon neither increased nor resulted in the appearance of either tumor antigen in those sera. In contrast, 59.2% and 75.4% of the patients with adenocarcinoma had positive serum levels of TAG-72 and CEA, respectively, prior to interferon. IFN-gamma and IFN-beta ser alone or in combination significantly increased serum TAG-72 or CEA in approximately 65% of those patients. The results suggest that interferon administration to patients with adenocarcinoma can result in increased serum levels of selected tumor-associated antigens used in the diagnosis of malignancy. These preliminary findings may be important in the development of new strategies to obtain more sensitive tumor antigen serum assays for the diagnosis and monitoring for disease progression of adenocarcinoma.</description><subject>Adenocarcinoma - blood</subject><subject>Adenocarcinoma - immunology</subject><subject>Adenocarcinoma - therapy</subject><subject>Antigens, Neoplasm - analysis</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoembryonic Antigen - analysis</subject><subject>Female</subject><subject>Glycoproteins - analysis</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Interferon Type I - therapeutic use</subject><subject>Interferon-gamma - therapeutic use</subject><subject>Medical sciences</subject><subject>Neoplasms - blood</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Pharmacology. Drug treatments</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LAzEQhhdRaq3-BCEH8baQbDZNepTiFxS86LnMJpM2spvUJFvoj_A_G3Dx6ulheJ95GeasmjPBVS3bVpxXc0qpqkUrm8vqKqXPMgpGxayasRWVSrF59f14dAa9RmJDJHmPBHs8QnbBk2BJwjgOREPUzgccungK3mkCPrsd-kJD8jiUTUgpaAcZDdn1Jx0OMWR0vpYNKX3YJ-I8OZRe9DkRMIPzLmWMxXe-0GIMPl1XFxb6hDcTF9XH0-P7-qXevD2_rh829Z5TmmvoBGNotBCqsVTZpZUIjAshaUOpAcqlEZ3RCkG2BixlRiLXVHam0RwsX1T3v73lzK8RU94OLmnse_AYxrRVVPJGLdW_IlsywZaCFvF2EsduQLM9RDdAPG2nR5f8bsohaehtBK9d-tPaVSs44_wHF46Lew</recordid><startdate>19910815</startdate><enddate>19910815</enddate><creator>GREINER, J. W</creator><creator>GUADAGNI, F</creator><creator>GOLDSTEIN, D</creator><creator>BORDEN, E. C</creator><creator>RITTS, R. E</creator><creator>WITT, P</creator><creator>LOBUGLIO, A. F</creator><creator>SALEH, M. N</creator><creator>SCHLOM, J</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19910815</creationdate><title>Evidence for the elevation of serum carcinoembryonic antigen and tumor associated glycoprotein-72 levels in patients administered interferons</title><author>GREINER, J. W ; GUADAGNI, F ; GOLDSTEIN, D ; BORDEN, E. C ; RITTS, R. E ; WITT, P ; LOBUGLIO, A. F ; SALEH, M. N ; SCHLOM, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h300t-ab511edc5582f08f6f7ea135570200da037d5bdc8ea74daf01d7e3c07bd2c3af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adenocarcinoma - blood</topic><topic>Adenocarcinoma - immunology</topic><topic>Adenocarcinoma - therapy</topic><topic>Antigens, Neoplasm - analysis</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoembryonic Antigen - analysis</topic><topic>Female</topic><topic>Glycoproteins - analysis</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Interferon Type I - therapeutic use</topic><topic>Interferon-gamma - therapeutic use</topic><topic>Medical sciences</topic><topic>Neoplasms - blood</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GREINER, J. W</creatorcontrib><creatorcontrib>GUADAGNI, F</creatorcontrib><creatorcontrib>GOLDSTEIN, D</creatorcontrib><creatorcontrib>BORDEN, E. C</creatorcontrib><creatorcontrib>RITTS, R. E</creatorcontrib><creatorcontrib>WITT, P</creatorcontrib><creatorcontrib>LOBUGLIO, A. F</creatorcontrib><creatorcontrib>SALEH, M. N</creatorcontrib><creatorcontrib>SCHLOM, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GREINER, J. W</au><au>GUADAGNI, F</au><au>GOLDSTEIN, D</au><au>BORDEN, E. C</au><au>RITTS, R. E</au><au>WITT, P</au><au>LOBUGLIO, A. F</au><au>SALEH, M. N</au><au>SCHLOM, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence for the elevation of serum carcinoembryonic antigen and tumor associated glycoprotein-72 levels in patients administered interferons</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1991-08-15</date><risdate>1991</risdate><volume>51</volume><issue>16</issue><spage>4155</spage><epage>4163</epage><pages>4155-4163</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Sera were collected from 111 patients diagnosed with adenocarcinoma or nonadenocarcinoma malignancies who received different schedules of interferon (IFN)-gamma or IFN-beta ser alone or in combination. Serum carcinoembryonic antigen (CEA) and tumor-associated glycoprotein-72 (TAG-72) antigen levels were measured to determine whether interferon could enhance the tumor shedding and, thereby, the serum level of either tumor antigen. Less than 10% of the sera samples from patients diagnosed with nonadenocarcinoma malignancies (e.g., hairy cell leukemia, melanoma) had positive titers of TAG-72 or CEA, and interferon neither increased nor resulted in the appearance of either tumor antigen in those sera. In contrast, 59.2% and 75.4% of the patients with adenocarcinoma had positive serum levels of TAG-72 and CEA, respectively, prior to interferon. IFN-gamma and IFN-beta ser alone or in combination significantly increased serum TAG-72 or CEA in approximately 65% of those patients. The results suggest that interferon administration to patients with adenocarcinoma can result in increased serum levels of selected tumor-associated antigens used in the diagnosis of malignancy. These preliminary findings may be important in the development of new strategies to obtain more sensitive tumor antigen serum assays for the diagnosis and monitoring for disease progression of adenocarcinoma.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>1907881</pmid><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-5472 |
ispartof | Cancer research (Chicago, Ill.), 1991-08, Vol.51 (16), p.4155-4163 |
issn | 0008-5472 1538-7445 |
language | eng |
recordid | cdi_proquest_miscellaneous_80732868 |
source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals |
subjects | Adenocarcinoma - blood Adenocarcinoma - immunology Adenocarcinoma - therapy Antigens, Neoplasm - analysis Antineoplastic agents Biological and medical sciences Biomarkers, Tumor - blood Carcinoembryonic Antigen - analysis Female Glycoproteins - analysis Humans Immunotherapy Interferon Type I - therapeutic use Interferon-gamma - therapeutic use Medical sciences Neoplasms - blood Neoplasms - immunology Neoplasms - therapy Pharmacology. Drug treatments |
title | Evidence for the elevation of serum carcinoembryonic antigen and tumor associated glycoprotein-72 levels in patients administered interferons |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T02%3A19%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence%20for%20the%20elevation%20of%20serum%20carcinoembryonic%20antigen%20and%20tumor%20associated%20glycoprotein-72%20levels%20in%20patients%20administered%20interferons&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=GREINER,%20J.%20W&rft.date=1991-08-15&rft.volume=51&rft.issue=16&rft.spage=4155&rft.epage=4163&rft.pages=4155-4163&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E80732868%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16151650&rft_id=info:pmid/1907881&rfr_iscdi=true |